Stolaroff MJ, Wells CW.
“Preliminary Results with New Psychoactive Agents 2C-T-2 AND 2C-T-7”.
Yearbook for Ethnomedicine. 1993 99-117.
Preliminary test reports of two new phenethylamines, 2C-T-2 and 2C-T-7, which show promise as facilitators in psychotherapy, are compared to virgin use of MDMA (1). The purpose of the tests was to determine whether there were sufficient useful properties of the drugs to warrant further study, without contra-indicating side-effects. Drugs were administered in a friendly, supportive atmosphere with serene natural surroundings. Participants were requested to fill out a one-page questionnaire within a few days following the experience rating physical symptoms and various areas of functioning, and provide pertinent comments. Objectionable physical symptoms were minimal, and the majority experienced improvement in functioning in such areas as clarity of thought, flow of insights, communication with others, visual perception, energy level, feelings of well-being, and expanded dimensions of thought. Most found the experience valuable, and a large majority (41 to 4) would repeat the experience.
SHULGIN ET AL. (1986) outline a protocol for establishing the characteristics of a new psychoactive compound. As described therein, once a compound has been found to be safe, with characteristics of interest, and the active range determined, it is introduced to a special group for evaluation. This is a stable group that has been specifically chosen for their broad experience with a variety of substances, their personal qualifications, and their known history in response to new substances and with each other.
The purpose of the current trials was to take two compounds which were found to show notable promise in the preliminary group trials and check the reactions of a broader spectrum of subjects having less personal experience with psychoactive agents. The two compounds are 2C-T-2 (SHULGIN & SHULGIN 1991: 557-561) and 2C-T-7 (SHULGIN & SHULGIN 1991: 567-571). To facilitate evaluation, first time use of both of these drugs was compared to the first time use of the well-known and widely used drug MDMA (ADAMSON 1985, BECK ET. AL. 1989, EISNER 1989, SHULGIN & SHULGIN 1991: 733-739). All trials were conducted before the placing of MDMA in Schedule 1 of the Controlled Substances act of 1970 and the enactment of the Controlled Substance Analogue Enforcement Act of 1986, which ostensibly applies to 2C-T-2, 2C-T-7, and similar compounds. This legislation accounts for the limited sample sizes in the trials of MDMA and 2C-T-7.
The objectives of the study were twofold. First, to determine whether the substances being explored show any potential usefulness for facilitating psychotherapy, for use as learning tools with regard to self, relationships, or the nature of reality, or as enhancers of functions like intuition, creativity, and clarity and range of thought. And second, whether they are free of readily noticeable, undesirable side effects. We hope through this preliminary study to stimulate further scientific research into these interesting compounds and to alert future researchers to possible contraindications.